Men's Weekly

.

AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license

Application for drug marketing registration duly submitted Super heavyweight items are expected to drive performance soaring

HONG KONG SAR - Media OutReach Newswire – 1 November 2024 - AIM Vaccine (06660.HK) announced on 1st November that the application for drug marketing registration of the Company's independently developed 13-valent pneumonia conjugate vaccine has been submitted to the National Medical Products Administration.

More Articles ...

  1. Light Show Illuminates the Liangma River
  2. 426 Major Projects Accelerating in Ordos
  3. VTEX and ChannelEngine Forge Powerful Alliance to Revolutionize the Ecommerce Landscape
  4. Siam Paragon Bangkok International Fashion Week 2024 Unveils the best of Thai and Asian Creativity And Reaffirms Siam Paragon As the Number One ‘Luxury Destination’
  5. EdgeProp announces winners of EdgeProp Excellence Awards 2024; City Developments, GuocoLand, SingHaiyi Group and UOL Group are Top Developers
  6. Mobile Shop Collaborates with Zand Bank
  7. "People in Ningbo: Rajesh and his Overseas Hometown's 14 Years" video series was launched at the Maritime Silk Road culture and tourism grand expo
  8. AstraZeneca Indonesia Recognized as the Best Places to Work for Three Consecutive Years
  9. The Hong Kong Institute of Surveyors Building Surveyors Conference 2024 "Transformative Trends in Building Surveying"
  10. AIM Vaccine’s heavyweight single-product mRNA RSV Vaccine obtained the clinical trial approval

Notice: Undefined offset: 1 in /httpdocs/templates/gk_university/html/pagination.php on line 18

Notice: Undefined offset: 1 in /httpdocs/templates/gk_university/html/pagination.php on line 34

Notice: Undefined offset: 2 in /httpdocs/templates/gk_university/html/pagination.php on line 34

Notice: Undefined offset: 3 in /httpdocs/templates/gk_university/html/pagination.php on line 34